CG Oncology, Inc. (NASDAQ:CGON) Shares Sold by Braidwell LP

Braidwell LP trimmed its position in shares of CG Oncology, Inc. (NASDAQ:CGON) by 4.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,170,875 shares of the company’s stock after selling 138,632 shares during the period. CG Oncology accounts for approximately 3.4% of Braidwell LP’s holdings, making the stock its 5th biggest position. Braidwell LP’s holdings in CG Oncology were worth $119,637,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in CGON. Ally Bridge Group NY LLC raised its holdings in shares of CG Oncology by 50.5% in the 3rd quarter. Ally Bridge Group NY LLC now owns 263,266 shares of the company’s stock worth $9,933,000 after purchasing an additional 88,390 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of CG Oncology during the third quarter valued at approximately $241,000. MetLife Investment Management LLC grew its position in CG Oncology by 103.2% during the third quarter. MetLife Investment Management LLC now owns 27,132 shares of the company’s stock valued at $1,024,000 after purchasing an additional 13,780 shares in the last quarter. BNP Paribas Financial Markets grew its position in CG Oncology by 876.9% during the third quarter. BNP Paribas Financial Markets now owns 26,660 shares of the company’s stock valued at $1,006,000 after purchasing an additional 23,931 shares in the last quarter. Finally, FMR LLC grew its position in CG Oncology by 83,581.6% during the third quarter. FMR LLC now owns 145,606 shares of the company’s stock valued at $5,494,000 after purchasing an additional 145,432 shares in the last quarter. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Stock Performance

Shares of CG Oncology stock opened at $34.10 on Friday. CG Oncology, Inc. has a 1 year low of $25.77 and a 1 year high of $50.23. The business has a 50-day moving average of $36.08 and a two-hundred day moving average of $34.62.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.30 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. On average, sell-side analysts predict that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of CG Oncology in a research report on Tuesday, November 12th. Roth Mkm started coverage on CG Oncology in a report on Tuesday, August 27th. They set a “buy” rating and a $65.00 price objective on the stock. UBS Group began coverage on shares of CG Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $60.00 target price on the stock. Roth Capital raised CG Oncology to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Bank of America restated a “buy” rating and issued a $65.00 price objective on shares of CG Oncology in a research report on Tuesday, October 8th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $63.88.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.